Key facts
- It has raised $54.0M; the latest was Early Stage VC ($27.8M) in Jun 2025.
- Notable investors include Lapam Capital, Co-Win Ventures, Pudong Capital, Shanghai Healthcare Capital, Shangshi Venture Investment — 13 tracked in total.
- Status: Privately Held (backing).
Investors
13+- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for BioTroy Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for BioTroy Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioTroy Therapeutics
Developer of target discovery pharmaceutical technology designed to promote the development of new first-in-class drugs. The company's technology focuses on tumor immunity and is used for multi-omics analysis of tumors, discovery of receptor ligands, research on target signal transduction pathways, antibody discovery and engineering, in vivo drug efficacy and large animal translational medicine, biomarkers and precision medicine, enabling patients to improve treatment effect.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- biotroy.cn/
- Ownership
- Privately Held (backing)
BioTroy Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioTroy Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioTroy Therapeutics in its N-PORT filings yet. We sweep new filings monthly.